- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Praxbind (idarucizumab) reimbursed in England, Ireland and Wales
17 February 2016 • Author: Victoria White
Boehringer Ingelheim has announced that Praxbind (idarucizumab) is now available to be used commercially in England, Ireland and Wales after the Health Technology Appraisal bodies in these countries agreed that it is eligible for full reimbursment without the need for a full appraisal.
Idarucizumab rapidly and specifically reverses the anticoagulant effect of Boehringer Ingelheim’s Pradaxa (dabigatran etexilate) for patients needing emergency surgery /urgent procedures or in situations of life-threatening or uncontrolled bleeding.
Idarucizumab received its European Commission marketing authorisation in November 2015 and is the first and only specific reversal agent for a NOAC to be granted a licence in the European Union.
Welcoming the news Professor Klaus Dugi, Medical Director and Managing Director Boehringer UK and Ireland said: “Anticoagulants offer important benefits to patients but there are going to be very rare circumstances when rapid reversal of the anticoagulation effect of dabigatran is beneficial. The decision by NICE, AWMSG and NCPE supports availability of, Idarucizumab, to doctors in England, Wales and Ireland is fantastic news.
“While we do not anticipate that it will be used regularly there can be no doubt that its availability will provide added confidence for prescribers when choosing dabigatran for their patients.
“I’m proud that Boehringer Ingelheim is again continuing to lead the way in anticoagulation care for patients in the United Kingdom and Ireland.”
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics